Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Clinical Care - Transplantation Regimen Toxicities and Engraftment Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AMLClinically Relevant Abstract

Shin Mineishi, MD1, John Magenau, MD2*, Attaphol Pawarode, MD1, Timothy Buck1*, Dawn Jones, RN1*, Koji Kato, MD1*, David Frame, Pharm, D1*, Lisa Kujawski, MD3, Harry Paul Erba, MD, PhD3, Yasser Khaled, MD1, Edward M. Peres, MD1, Oleg I. Krijanovski, PhD, MD1, Pavan Reddy, MD1, Carrie Kitko, MD1, Sung Choi, MD1, Gregory A. Yanik, MD1*, Thomas Braun, PhD1*, James L.M. Ferrara, MD1 and John E. Levine, MD1

1Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI
2University of Michigan, Ann Arbor, MI
3Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI

Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization

Elina Delgado1*, Charles F. LeMaistre, MD1, Carlos Bachier1*, Brad Smith, PhD2*, Guillermo López-González1*, Maureen Hougham1*, Shawn Kaleel1* and Paul Shaughnessy, MD1

1Texas Transplant Institute, San Antonio, TX
2Altarum, San Antonio, TX

Relationship of Targeted Busulfan Exposure to Engraftment in Children Undergoing Myeloablative Matched Sibling Donor Transplantation for Sickle Cell Disease

Marianne E. McPherson, MD1, Don Hutcherson, RPh2*, Ellen Olson, CPNP3*, Ann Haight, MD1, John Horan, MD, MPH1* and Kuang-Yueh Chiang, MD, PhD1*

1Pediatric Hematology/Oncology, Emory University School of Medicine, Atlanta, GA
2Department of Pharmacy, Emory Healthcare, Atlanta, GA
3Pediatric Hematology/Oncology, Children's Healthcare of Atlanta, Atlanta, GA

Outcomes of Allogeneic Stem Cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive Therapy with Curative IntentClinically Relevant Abstract

Sergio Giralt1, Rima M Saliba, Ph.D2*, Gabriela Rondon3*, Leandro de Padua Silva4*, Amin M. Alousi5*, Uday Popat3*, Marco De Lima3*, Borje Andersson6*, Partow Kebriae, MD7*, Paolo Anderlini3*, Chitra Hosing, MD8, Roy Jones3*, Elizabeth J. Shpall, MD9, Richard E. Champlin5* and Issa F. Khouri2*

1Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX
3Stem Cell Trans./Stem Therapy, Univ. of Texas, Houston, TX
4Stem Cell Transplantation and Cellular Therapies, University of Texas M.D. Anderson Cancer Center, Houston, TX
5Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
6University of Texas MD Anderson, Houston, TX
7Pediatrics, U.T. M.D. Anderson Cancer Center, Houston, TX
8M.D. Anderson Cancer Center, Houston, TX
9Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Novel Tyrosine Kinase Inhibitor Therapy Before Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid LeukemiaClinically Relevant Abstract

Leandro de Padua Silva1, Jorge Cortes1*, Elias Jabbour2, Sergio Giralt1*, Partow Kebriaei1*, Susan O'Brien2*, Amin Alousi1*, Muzaffar Qazilbash1*, Gabriela Rondon1*, Farhad Ravandi1*, Rachel Ribeiro1*, Chitra Hosing1*, Hagop Kantarjian2*, Richard Champlin1* and Marcos De Lima1*

1Department of Stem Cell Transplantation & Cell Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant

Christy Stotler, DO, Lisa Rybicki*, Matt Kalaycio, MD*, Robert Dean, Edward A. Copelan, MD, Ronald Sobecks, MD*, Brad Pohlman, MD*, Steven Andresen, DO*, John Sweetenham, MD*, Kelly Cherni, RN*, Josephine Chan* and Brian J. Bolwell, MD

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Possible Role of Engraftment Syndrome in Myelodysplastic Syndrome after Autologous Transplants

Yi Kong Keung, MD1, Michael W Beaty2*, Mark Pettenati3*, Denise Levitan, MD4, Istvan Molnar, MD5, Mohan C. Thakuri, MD6, Julia Cruz, MD7* and David Duane Hurd, MD4

1Comprehensive Cancer Center, Wake Forest University, Winston Salem, NC
2Pathology, Wake Forest University, Winston-Salem, NC
3Genetics, Wake Forest University, Winston-Salem, NC
4Wake Forest University, Winston Salem, NC
5Bayer HealthCare Pharmaceuticals, Pine Brook, NJ
6Cancer Care of Western North Carolina, Asheville, NC
7School of Medicine, Wake Forest University, Winston Salem, NC

Impact of Donor/Recipient Major ABO Mismatch on Allogeneic Transplantation Outcome According to Stem Cell Source: Results from An 809-Patient Retrospective StudyClinically Relevant Abstract

Nicolas Blin, MD1*, Richard Traineau, MD2*, Régis de Latour, MD, PhD3*, Marie Robin, MD, PhD3*, Agnes Devergie, MD3*, Patricia Ribaud, MD3* and Gerard Socie, MD, PhD3*

1Hematology, CHU de Nantes, Nantes, France
2Hemobiology, Saint-Louis Hospital, Paris, France
3Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France

Monitoring of  Post-Transplant Hematopoiesis in Patients Receiving High-Dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) with Autograft: Lack of Detection of Remarkable Abnormalities

Anna Guidetti, MD1*, Carmelo Carlo-Stella, MD2, Alberto Rocci, MD3*, Liliana Devizzi, MD1*, Daniela Sia, PhD1*, Adele Testi, PhD4*, Michele Magni, MD1*, Massimo Di Nicola, MD1*, Paola Matteucci, MD1*, Alessandra Risso, PhD3*, Marco Ruella, MD3*, Corrado Tarella, MD3* and Alesandro M. Gianni, MD2*

1Medical Oncology, Istituto Nazionale Tumori, Milano, Italy
2Medical Oncology, Istituto Nazionale Tumori and University of Milano, Milano, Italy
3Hematology and Molecular Biotechnology Center, University of Torino, Torino, Italy
4Pathology, Istituto Nazionale Tumori, Milano, Italy

Delayed Platelet Engraftment and Early Increased Creatinine after Stem Cell Transplant Predicts Sustained Remission in Pediatric Leukemia

Meera Sridhar, MS1*, Christopher C. Dvorak, MD2, Rajni Agarwal, MD3* and Joshua D. Schiffman, MD4*

1Stanford University School of Medicine, Stanford, CA
2UCSF, San Francisco, CA
3Pediatric Stem Cell Transplantation, Stanford Univ. School of Medicine, Palo Alto, CA
4Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT

CD8-Depleted Donor Lymphocyte Infusions Convert Mixed into Complete Donor T-Cell Chimerism after T-Cell Depleted Allogeneic Stem Cell Transplantation

Ralf G Meyer, MD1*, Eva M Wagner, MD1*, Timo Schmitt1*, Klaus Bender, PhD2*, Udo F Hartwig, PhD1*, Christoph Huber, MD1*, Karin Kolbe, MD1* and Wolfgang Herr, MD1*

1Medical Department 3, Hematology and Oncology, Johannes-Gutenberg-University, Mainz, Germany
2Department of Legal Medicine, Johannes-Gutenberg-University, Mainz, Germany

An Analysis of Toxicities and Time to Engraftment Associated with Three Distinct Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving Autologous Hematopoetic Stem Cell TransplantationClinically Relevant Abstract

Ila Maewal, PharmD1*, Andy J Kurtzweil, PharmD1*, Jamie F Shapiro, PharmD2*, Michael D Westmoreland, PharmD1*, Roland L Bassett3* and Sergio Giralt, MD4

1Division of Pharmacy, M.D. Anderson Cancer Center, Houston, TX
2H. Lee Moffitt Cancer Center and Research Institute
3M.D. Anderson Cancer Center
4M.D. Anderson Cancer Center, Houston, TX

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 YearsClinically Relevant Abstract

Mohamed L. Sorror, MD, MSc1*, Barry Storer, PhD1*, Brenda M. Sandmaier, MD1*, David G. Maloney, MD, PhD1*, Georg Franke, MD2*, Judith Shizuru, MD, PhD3*, Thomas Chauncey, MD4*, Edward Agura, MD5, Richard T. Maziarz, MD6, Firoozeh Sahebi, MD7*, Amelia A Langston, MD8, James C. Wade, MD, MPH9, Michael Maris, MD10, Benedetto Bruno, MD11*, Andrew M. Yeager, MD12, Michael Pulsipher, MD13, Finn Petersen, MD14, Wolfgang A. Bethge, MD15*, Peter A. McSweeney, MD10, Dietger Niederwieser, MD16*, Karl G. Blume, MD3* and Rainer F. Storb, MD1

1Fred Hutchinson Cancer Research Center/ University of Washington, Seattle, WA
2University of Leipzig, Laipzig, Germany
3Stanford University Medical Center, Stanford, CA
4VA Puget Sound Health Care System/ Fred Hutchinson Cancer Research Center/ Univeristy of Washington, Seattle, WA
5Baylor University Medical Center, Dallas, TX
6Oregon Health & Science University, Portland, OR
7City of Hope Nattional Medical Center, Duarte, CA
8School of Medicine, Emory University, Atlanta, GA
9Medical College of Wisconsin, Milwaukee, WI
10Rocky Mountain Cancer Center, Denver, CO
11University of Torino, Torino, Italy
12University of Arizona, Tucson, AZ
13University of Utah Medical Center, Salt Lake City, UT
14LDS Hospital, Salt Lake City, UT
15University of Tuebingen Medical Center, Tuebingen, Germany
16University of Leipzig, Leipzig, Germany

Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity TransplantsClinically Relevant Abstract

Joseph Maslak1*, Daniel Kaul, MD2*, James Connelly, MD3*, Shin Mineishi, MD1, John E. Levine, MD1, Edward M. Peres, MD1, Carrie Kitko, MD1, Sung W. Choi, MD1, Yasser Khaled, MD1, Oleg I. Krijanovski, PhD, MD1, Stefanie Digiandomenico1*, Eric White, MD2*, Thomas Braun, PhD1*, Pavan Reddy, MD1, Attaphol Pawarode, MD1, James L.M. Ferrara, MD1 and Gregory A. Yanik, MD1*

1Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI
2Department of Internal Medicine, University of Michigan
3Department of Pediatrics, University of Michigan

No Impact of Postremission Consolidation Chemotherapy Before Allogeneic Transplant in Patients with First Remission Acute Myeloid Leukemia with Intermediate or High Risk Cytogenetics

Lisa O. Sproat, MD, MSW, Brian Bolwell, Lisa Rybicki*, Matt Kalaycio*, Robert Dean, Ronald Sobecks, Brad Pohlman, Steve Andresen*, Shawnda Sungren*, Josephine Chan*, John Sweetenham* and Ed Copelan*

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

*signifies non-member of ASH